Long-term follow-up after a switch to bictegravir, emtracitabine, tenofovir alafenamide from dolutegravir, abacavir, lamivudine

Authors
Category Primary study
JournalOpen Forum Infectious Diseases
Year 2020
This article has no abstract
Epistemonikos ID: 59343d98715b55d11574c274e5a91b806b0fb66b
First added on: Nov 24, 2021